Curosurf® (poractant alfa) is indicated for the treatment of Respiratory Distress Syndrome (RDS) in premature infants. To treat premature infants requiring mechanical ventilation with clinical signs of surfactant deficiency and/or RDS confirmed by x-ray, the first dose of CUROSURF has to be administered as soon as possible, preferably within 6 hours of birth. Based on the results of clinical trials best results are obtained when CUROSURF is administered early in the course of RDS in infants with gestational age < 30 weeks or birth weight < 1500 g.
For complete prescribing information, please contact Methapharm.
Provocholine® (methacholine chloride USP) is indicated for the diagnosis of bronchial airway hyperresponsiveness in subjects who do not have clinically apparent asthma.
For complete prescribing information, please consult the Product Insert. Please note the following Prescribing Information is intended for US Healthcare Professionals. The product discussed herein may have different product labeling in different countries. For the prescribing information related to a specific country, please contact Methapharm. For information on Provocholine, please click here. Product Insert and SDS available on Provocholine website. For clinical trial inquiries, please click here.